CPAP for Premature Birth
(PLANT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether using a breathing support called CPAP (Continuous Positive Airway Pressure) immediately after birth helps late preterm newborns (born between 34 and 37 weeks) breathe better and avoid additional respiratory support. The study compares babies receiving CPAP with those receiving the usual care without it. Newborns eligible for the trial are those born by C-section and breathing independently. The trial aims to determine if early CPAP can reduce the need for intensive care in these infants. As an unphased trial, this study provides a unique opportunity to contribute to important research that could improve care for future newborns.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications.
Do I need to stop my current medications for this trial?
The trial information does not specify whether participants need to stop taking their current medications.
What prior data suggests that Continuous Positive Airway Pressure is safe for late preterm newborns?
Research has shown that using Continuous Positive Airway Pressure (CPAP) early in newborns is safe and effective. One study found that starting CPAP soon after birth reduced the need for more invasive breathing support, like machines, by 45%. As a result, fewer babies required extra help to breathe.
Another study discovered that using CPAP longer in stable premature babies might aid lung growth and function. This suggests that newborns generally tolerate CPAP well.
While some research noted that CPAP didn't significantly reduce certain risks, such as death or lung problems, in very early preterm babies, it still revealed no major safety concerns. Overall, these findings suggest that CPAP is a safe option to help newborns breathe more easily right after birth.12345Why are researchers excited about this trial?
Researchers are excited about the trial for prophylactic delivery room Continuous Positive Airway Pressure (CPAP) for premature infants because it explores a proactive approach to supporting newborns' breathing right from birth. Unlike the standard of care, which involves using CPAP only when breathing difficulties become evident, this approach administers CPAP immediately to infants who are breathing spontaneously. This early intervention might help prevent respiratory issues before they escalate, potentially reducing complications and improving outcomes for premature babies. The trial aims to determine if this early, preventive use of CPAP can make a significant difference in the health of these vulnerable infants.
What evidence suggests that Continuous Positive Airway Pressure is effective for reducing NICU admissions in late preterm newborns?
Research has shown that using Continuous Positive Airway Pressure (CPAP) immediately after birth can help premature babies breathe better independently. In this trial, some infants will receive Prophylactic Delivery Room Continuous Positive Airway Pressure, which involves administering CPAP right after birth. Studies have found that starting CPAP early might reduce the need for more intense breathing support later. This treatment has been linked to fewer cases of bronchopulmonary dysplasia and a lower risk of death in very premature infants. Early CPAP can also reduce the need for mechanical ventilation, which is more invasive. Overall, early CPAP appears promising for improving breathing outcomes in premature newborns.26789
Who Is on the Research Team?
Birju Shah, MD
Principal Investigator
Univeristy of Oklahoma Health Sciences Center
Are You a Good Fit for This Trial?
This trial is for late preterm infants born by C-section, specifically those with a gestational age between 34 and less than 37 weeks. Infants must be inborn (delivered at the hospital where the trial is conducted). Those with major congenital anomalies or conditions that severely limit life expectancy, such as pulmonary hypoplasia, cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Neonates receive either prophylactic DR-CPAP or standard care immediately after birth
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Continuous Positive Airway Pressure
- Prophylactic Delivery Room Continuous Positive Airway Pressure
Trial Overview
The study tests if giving early prophylactic Continuous Positive Airway Pressure (CPAP), with or without extra oxygen, to spontaneously breathing late preterm infants can reduce the need for additional respiratory support and NICU admissions compared to not using early CPAP.
How Is the Trial Designed?
If the infant is spontaneously breathing and allocated to the experimental arm, s/he will receive 20 min of 5 cm H2O of prophylactic continuous airway pressure using either a face mask or the appropriate size of nasal prong.
Alternatively, spontaneously breathing infants assigned to control group will receive the standard of care with no prophylactic delivery room continuous positive airway pressure (CPAP). In both groups, CPAP can be used to help babies with persistent labored breathing or cyanosis after the initial steps as per the participating institution's neonatal resuscitation protocol. At any time, if the patient does not present spontaneous breathing, an escalation on the resuscitation measures will be performed and the study intervention will be terminated.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Oklahoma
Lead Sponsor
Indiana University
Collaborator
Pontificia Universidad Catolica de Chile
Collaborator
Columbia University
Collaborator
St. Louis University
Collaborator
University of Alberta
Collaborator
Published Research Related to This Trial
Citations
Prophylactic or very early initiation of continuous positive ...
When compared to mechanical ventilation, prophylactic nasal CPAP in very preterm infants reduces the incidence of BPD, the combined outcome of death and BPD, ...
Study Details | NCT05204719 | Prophylactic DR-CPAP on ...
Patient characteristics, delivery room variables, and neonatal outcomes will be recorded in a secure password protected REDCap database. Official Title.
Acceptability of immediate CPAP for preterm infants in the ...
Initiating continuous positive airways pressure (CPAP) immediately after birth may reduce CPAP failure, the need for ventilation, and surfactant ...
4.
pilotfeasibilitystudies.biomedcentral.com
pilotfeasibilitystudies.biomedcentral.com/articles/10.1186/s40814-024-01552-xImpact of early continuous positive airway pressure in the ...
We hypothesize that in such settings, early continuous positive airway pressure will reduce the rate of failure and therefore preterm mortality.
Prophylactic surfactant therapy in the era of less invasive ...
A meta-analysis showed that first-intention CPAP with selective surfactant administration reduced the risk of BPD or death compared with routine ...
Impact of early continuous positive airway pressure in the ...
In HICs, the use of early CPAP, within 15 min of delivery, has been shown to decrease the need for mechanical ventilation by up to 45% and is ...
Extended Continuous Positive Airway Pressure in Preterm ...
Extending CPAP in stable preterm infants in the neonatal ICU may be a nonpharmacologic and safe therapy to promote lung growth and function.
Continuous positive airway pressure for term and ≥34+0 ...
Respiratory distress affects up to 7% of term (≥37+0 weeks' gestational age) newborn infants after birth, and 9% of late preterm (34+0–36+6 ...
Nasal CPAP or Intubation at Birth for Very Preterm Infants
In infants born at 25-to-28-weeks' gestation, early nasal CPAP did not significantly reduce the rate of death or bronchopulmonary dysplasia, as compared with ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.